We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Auto-summary of recent filing activity and financial trends · not investment advice
Samsung Biologics has recently seen a frequent occurrence of 'Other' and 'Correction' disclosures, alongside the consistent submission of regular filings like business reports, audit reports, and quarterly reports. For the first quarter of 2026, the company recorded approximately KRW 1.2571 trillion in revenue and approximately KRW 469.2 billion in net profit. This suggests robust business activities and adjustments related to its disclosures.
Latest filings collected from DART (electronic disclosure system)